These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 26860624)

  • 1. Immune checkpoint therapy for non-small-cell lung cancer: an update.
    Xia B; Herbst RS
    Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors in lung cancer: past, present and future.
    Seetharamu N; Budman DR; Sullivan KM
    Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
    Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
    Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
    Moon EK; Langer CJ; Albelda SM
    Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
    Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Advanced Lung Cancer.
    Asmar R; Rizvi NA
    Cancer J; 2015; 21(5):383-91. PubMed ID: 26389763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.